Clinical Trial Update: The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing Shengmai San to prevent cardiac toxicity from sequential anthracycline and trastuzumab therapy in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiotoxicity

Drugs mentioned

• Shengmai San

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Cardiotoxicity Induced by Drug Therapy for Breast Cancer | Phase 3 | Status: RECRUITING